You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

1630 Results
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Sep 2025
Drug
Other Name(s): Truqap™
Oct 2025
Drug
Other Name(s): Rybrevant®
Nov 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Funding:
Exceptional Access Program
    alectinib - Adjuvant treatment of ALK-positive non-small cell lung cancer, according to specific criteria
Nov 2025
Regimen
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Exceptional Access Program
    acalabrutinib - In Combination with Bendamustine and Rituximab for Mantle Cell Lymphoma, based on criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Updated
Jan 2026
Regimen
Cancer Type:
Genitourinary, 
Penile
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
    capecitabine
New
Jan 2026
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
New
Jan 2026

Pages